Translumina

What Translumina does

Translumina is a privately held global manufacturer of interventional cardiovascular medical devices, headquartered in Hechingen, Germany, with manufacturing operations in Germany (Hechingen), the Netherlands (Helmond), and India (Dehradun), and approximately 600 employees worldwide. The company's product portfolio is concentrated in three categories used during percutaneous coronary interventions: drug eluting stents (permanent implantable scaffolds with anti-proliferative drug coatings), drug eluting balloons (for localized drug delivery without permanent implant), and PTCA balloons (for coronary artery dilation). Translumina's underlying technology platform includes proprietary drug application and coating methods, notably extended through the June 2023 acquisition of Netherlands-based Blue Medical Devices.

The company generates revenue through B2B hardware sales of cardiovascular devices to hospitals and healthcare providers, using quote-based enterprise pricing that is not publicly disclosed. Translumina's go-to-market combines 60+ channel partners across 40+ countries with direct operations in selected markets — most recently the UAE, where direct operations were launched in May 2024 — and acquired distribution assets including Munich-based Lamed GmbH (June 2023) in Germany. Manufacturing is certified to ISO 13485:2016 and ISO 9001:2015, and Translumina positions itself as India's largest domestic player in the coronary stents market. The company maintains an active sub-brand, TransAcademy, aimed at clinician education, and pursues a horizontal segmentation strategy targeting hospitals performing interventional cardiology.

Name

Translumina

Legal name

Translumina

Website

https://translumina.de

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

11–50 employees

Short description

Translumina is a privately held, Germany-headquartered manufacturer of interventional cardiovascular devices — drug eluting stents, drug eluting balloons, and PTCA balloons — selling to hospitals across 40+ countries via channel partners and direct operations in markets such as the UAE.

Ownership category

akta.pro rank

Product category

Interventional Cardiovascular Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Coronary Stents & Drug-Eluting Technologies (HLAHAFAA)

akta.pro secondary industry

Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy) (HLAHAFAE)

Keywords

• Drug eluting stents
• Drug eluting balloons
• PTCA balloons
• Interventional cardiology devices
• Cardiovascular medical devices

Headquarters

HQ city

Hechingen

HQ country

Germany

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

1. Cardiovascular Medical Devices Sales: Sale of interventional cardiovascular devices including drug eluting stents, drug eluting balloons, and PTCA balloons to hospitals and healthcare providers globally

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Core offering

Translumina manufactures and sells interventional cardiovascular devices, specifically drug eluting stents, drug eluting balloons, and PTCA balloons, used by hospitals and healthcare providers in coronary and vascular interventions. The company runs three ISO 13485:2016 and ISO 9001:2015 certified manufacturing facilities in India, Germany, and the Netherlands, and distributes its products globally through 60+ channel partners across 40+ countries supplemented by direct operations in select markets.

Product overview

Translumina offers a unified portfolio of three core interventional cardiovascular device categories: Drug Eluting Stents (permanent implantable scaffolds with anti-proliferative drug coating), Drug Eluting Balloons (for localized drug delivery without permanent implant), and PTCA Balloons (for coronary artery dilation during angioplasty). These products work synergistically to address different stages and approaches to coronary intervention treatment. The company operates manufacturing facilities in India, Germany, and the Netherlands and has expanded through acquisitions of Blue Medical Devices (Netherlands, 2023) and Lamed GmbH (Germany, 2023).

Differentiator

Problem solved

Functional benefit

Brands

• TransAcademy: Educational/training platform mentioned on the website

Products and services

• Drug Eluting Stents State-of-the-art drug-eluting stents designed for cardiovascular care, featuring advanced drug-eluting technology to prevent restenosis and improve patient outcomes in coronary interventions. Sold to hospitals and healthcare providers performing interventional cardiology procedures.
• Drug Eluting Balloons Cutting-edge drug-eluting balloons for vascular treatment, enabling localized drug delivery during percutaneous interventions without permanent implant placement. Sold to hospitals and healthcare providers.
• PTCA Balloons Advanced coronary balloons for percutaneous transluminal coronary angioplasty (PTCA), designed to dilate narrowed coronary arteries during cardiovascular interventions. Sold to hospitals and healthcare providers performing angioplasty procedures.

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Blue Medical DevicescoreStrategic or Co-development Partner · 1 June 2023In June 2023, Translumina acquired Netherlands-based Blue Medical Devices to incorporate its drug application technology into Translumina's product range. The acquisition enhances Translumina's portfolio of interventional cardiovascular devices, specifically expanding drug-coated balloons and other coronary interventions capabilities.
• Lamed GmbHcoreChannel Partner/ Reseller/ Distributor · 1 June 2023Translumina acquired Munich-based Lamed GmbH, a vascular and cardiovascular products distributor, to expand its footprint in Germany. The deal aims to strengthen Translumina's presence in Europe's largest interventional cardiology market and leverage Lamed's extensive hospital network.

Scale indicators5 records

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• Boston Scientific: Major player in interventional cardiology with Promus DES and drug-eluting balloons. Direct competitor to Translumina in coronary stents and DEB.
• Abbott: Global leader in interventional cardiology with Xience drug-eluting stents serving as the gold standard. Directly competes with Translumina in coronary stent procurement at major hospitals worldwide.
• Medtronic: Major cardiovascular device manufacturer with Resolute DES family and broad interventional cardiology portfolio. Competes with Translumina across coronary intervention segments globally.
• MicroPort Scientific Corporation: Chinese-origin cardiovascular device company with coronary stents (Firehawk) and broader structural heart portfolio. Competes with Translumina in emerging markets and Europe.
• Terumo Corporation: Japanese medical device conglomerate with interventional cardiology offerings (including acquired assets from Abbott). Established incumbent in the same cardiovascular procedure suite Translumina serves.

Direct peers

• B. Braun: European-headquartered interventional cardiology competitor with drug-eluting stents (Coroflex) and DEB portfolio. Particularly relevant as Translumina has built manufacturing in Germany competing in B. Braun's home market.
• Sahajanand Medical Technologies: Indian domestic coronary stent manufacturer with Supraflex/Yukon DES lines. Most direct domestic competitor to Translumina in the Indian coronary stent market.
• Meril Life Sciences: Indian interventional cardiology and structural heart device maker with drug-eluting stents and balloons. Comparable Indian mid-cap competitor targeting both domestic and export markets.
• Lepu Medical: Chinese manufacturer of drug-eluting stents and balloons with global distribution. Comparable mid-sized Asian-origin competitor with cost-competitive manufacturing and expanding international reach.

Emerging players

• iVascular: European-headquartered emerging competitor in drug-eluting balloons and peripheral vascular intervention. Comparable in scale and category focus on DEB technology overlap with Translumina's Blue Medical portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xtwitter.com/translumina_in
• YouTubeyoutube.com/c/TransluminaTherapeutics
• Facebookfacebook.com/translumina
• LinkedInlinkedin.com/company/translumina-therapeutics
• Instagraminstagram.com/translumina

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Translumina